首页> 外文期刊>Neuroscience Research: The Official Journal of the Japan Neuroscience Society >Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain.
【24h】

Post-injury administration of minocycline: an effective treatment for nerve-injury induced neuropathic pain.

机译:米诺环素的损伤后给药:神经损伤引起的神经性疼痛的有效治疗。

获取原文
获取原文并翻译 | 示例
       

摘要

Neuropathic pain is an intractable clinical problem, affecting millions of people worldwide. Preemptive administration of minocycline has been confirmed useful for treating neuropathic pain by inhibiting spinal microglia activation and consequently lowering proinflammatory cytokine expression. However, most patients with neuropathic pain have no chance to receive preemptive treatment and it remains unclear whether there is a therapeutic time window for post treatment with minocycline. The present study is to confirm the effect and the therapeutic time window of intrathecal minocycline on spinal nerve ligation (SNL)-induced neuropathic pain after lesion. Behavioral test and immunohistochemistry are utilized to determine the variation of mechanical allodynia and microglia phosphorylated-p38 (p-p38) expression respectively after intrathecal minocycline. Results showed that post-injury intrathecal minocycline attenuated mechanical allodynia effectively together with inhibiting spinal microglia p-p38 expression on post operative day (POD) 1, POD 3 and POD 7. Additionally, results from POD 10 and POD 21 showed that intrathecal minocycline suppressed spinal microglia p-p38 expression but without any effects on reversing mechanical allodynia. It is concluded that post-injury intrathecal minocycline is an effective therapeutic intervention for treating SNL-induced neuropathic pain by inhibiting spinal microglia activation. Accordingly, there is indeed a therapeutic time window for post-injury intrathecal minocycline, which is the initiation stage of neuropathic pain development.
机译:神经性疼痛是一个棘手的临床问题,影响着全球数百万人。已证实抢先给药美满霉素可通过抑制脊髓小胶质细胞活化并因此降低促炎细胞因子表达来治疗神经性疼痛。然而,大多数患有神经性疼痛的患者没有机会获得先发制人的治疗,并且尚不清楚米诺环素治疗后是否有治疗时间窗。本研究旨在证实鞘内注射米诺环素对脊髓神经结扎(SNL)引起的病变后神经性疼痛的作用和治疗时间窗。行为测试和免疫组织化学分别用于确定鞘内注射米诺环素后机械性异常性疼痛和小胶质细胞磷酸化的p38(p-p38)表达的变化。结果显示,损伤后鞘内米诺环素在术后第1天(POD)1,POD 3和POD 7上有效地减轻了机械性异常性疼痛并抑制了脊髓小胶质细胞p-p38的表达。此外,POD 10和POD 21的结果表明鞘内米诺环素被抑制脊髓小胶质细胞p-p38表达,但对逆转机械性异常性疼痛没有任何影响。结论是,鞘内注射米诺环素是通过抑制脊髓小胶质细胞活化来治疗SNL诱导的神经性疼痛的有效治疗手段。因此,确实存在损伤后鞘内米诺环素的治疗时间窗,这是神经性疼痛发展的起始阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号